USA - NASDAQ:CAI - US1421521071 - Common Stock
ChartMill assigns a Buy % Consensus number of 87% to CAI. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-13 | Guggenheim | Maintains | Buy -> Buy |
| 2025-08-13 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-08-13 | Citigroup | Maintains | Buy -> Buy |
| 2025-07-15 | Evercore ISI Group | Initiate | Outperform |
| 2025-07-14 | TD Cowen | Initiate | Buy |
| 2025-07-14 | Guggenheim | Initiate | Buy |
| 2025-07-14 | Wolfe Research | Initiate | Outperform |
| 2025-07-14 | JP Morgan | Initiate | Overweight |
| 2025-07-14 | Citigroup | Initiate | Buy |
| 2021-06-30 | Keefe, Bruyette & Woods | Downgrade | Outperform -> Market Perform |
| 2021-06-21 | William Blair | Downgrade | Outperform -> Market Perform |
| 2021-06-18 | B. Riley Securities | Downgrade | Buy -> Neutral |
12 analysts have analysed CAI and the average price target is 39.91 USD. This implies a price increase of 60.4% is expected in the next year compared to the current price of 24.88.
The consensus rating for CARIS LIFE SCIENCES INC (CAI) is 86.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering CARIS LIFE SCIENCES INC (CAI) is 12.